5IR Funds Leads $10M Round in GreatX to Unlock Real Estate Yield Through DeFi
At the intersection of real-world assets, behavioral finance, and stablecoin infrastructure, GreatX introduces a programmable liquidity layer for the $12.3 trillion of income-producing real estate currently trapped in long-term, illiquid structures.
Rather than tokenizing real estate titles, GreatX mints U.S. Treasury–backed tokens that can be optionally assigned to revenue-generating hotel properties—activating yield from both cashflow and appreciation, all while preserving principal. The result: a secure, composable asset that behaves like a stablecoin but performs like a portfolio.
'We believe GreatX represents the next evolution in RWA tokenization: asset-backed, behaviorally designed, and DeFi-native from inception,' said David Carstens, Founder and General Partner at 5IR Funds. 'In a world awash with speculative real estate plays, GreatX delivers something that actually works—for both yield seekers and protocol composability. This is the kind of real-world capital stack DeFi has been waiting for.'
Backed by the Patel Family Office, a 3rd-generation real estate investment and management firm based in Dallas with deep experience in owning and managing hotels globally , GreatX is launching with institutional-grade hospitality assets in the U.S. and a 10,000+ investor pipeline spanning North America, the Middle East, and Asia.
'Our goal was never just tokenization—it was transformation,' said Kim Diamond, Co-Founder of GreatX and former Managing Director at Standard & Poor's. 'We've spent our careers building real-world portfolios. With GreatX, we've architected a product that speaks the native language of DeFi, but brings the full weight of institutional real estate discipline.'
The raise will accelerate GreatX's platform rollout, regulatory pathways, and token issuance. The protocol is set to launch its first tranche of asset-linked, assignable tokens by Q4 2025.
Why It Matters
• $380T Global Real Estate is the world's largest store of wealth—and its least liquid
• $205B Stablecoins represent programmable capital with no native yield mechanism
• GreatX bridges both: U.S. Treasuries + Real Estate Cashflow = Capital-Protected RWA Yield
About GreatX
GreatX is a DeFi-native platform unlocking real estate equity via U.S. Treasury-backed tokens that offer stable yield, capital protection, and upside exposure through optional property assignment. Built in partnership with the Patel Family Office and led by real estate and structured finance veterans, GreatX enables global investors to access institutional real estate returns—without the friction of traditional real estate ownership.
More: www.greatx.com
Contact:
[email protected]
About 5IR Funds
5IR Funds is a venture capital fund backing the breakthrough companies and foundational technologies of the Fifth Industrial Revolution. With a $200 million target fund , 5IR makes early-stage investments in pioneering companies across artificial intelligence (AI), blockchain, quantum computing, advanced materials, and virtual reality (VR). Led by a team of experienced technologists, entrepreneurs, and intellectual property experts, 5IR provides more than capital—it delivers strategic partnership, an extensive network, and the specialized guidance needed to build defensible, market-defining businesses.
More: www.5irfunds.com
Contact:
[email protected]
Contact Information:
5IR Funds
Zachary Todd
972-755-5420
Contact via Email
www.5irfunds.com
Read the full story here: 5IR Funds Leads $10M Round in GreatX to Unlock Real Estate Yield Through DeFi
Press Release Distributed by PR.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company's long-term trajectory. The 'Buy' rating remains unchanged, signaling confidence in GeneDx's market position and its potential to capture a growing share of the precision medicine space. A modern office space where the team is engaging in business development and management services. GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement. The price target hike reflects Guggenheim's view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx's technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx's role in transforming how rare and complex diseases are diagnosed and managed. While we acknowledge the potential of WGS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WGS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505
Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least two prior therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions with unmet medical need. A biopharmaceutical executive discussing plans with a government laboratory. SGR-1505 is a selective MALT1 inhibitor currently in clinical development. Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma, and treatment-resistant forms present significant challenges for patients and clinicians. Schrödinger's approach to drug discovery gives it a unique advantage in targeting such difficult diseases. The company is best known for its computational platform that integrates physics-based modeling and advanced algorithms to design novel compounds with greater precision and efficiency. This model-driven strategy makes Schrödinger one of the few healthcare companies at the forefront of computational drug discovery—a field that blends molecular science with cutting-edge software to identify and optimize potential therapies faster than traditional methods. With the FDA's Fast Track status, SGR-1505 may benefit from more frequent interaction with the agency and potential eligibility for accelerated approval, positioning Schrödinger to advance an important treatment option while reinforcing its growing role as a technology-driven innovator in the pharmaceutical sector. While we acknowledge the potential of SDGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SDGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
